DFSV vs IBB
Dimensional US Small Cap Value ETF vs iShares Biotechnology ETF
- • DFSV has the lower expense ratio at 0.31% vs 0.44% for IBB.
Side-by-side metrics
| Metric | DFSV | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.31% | 0.44% |
Dividend yield Trailing 12-month yield. | — | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $27.77B | $11.50B |
YTD return | 19.52% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.96 | 0.60 |
P/E ratio | 13.30 | 25.48 |
Last price | $39.35 | $217.75 |
Inception | — | — |
Issuer | Dimensional | iShares |
DFSV top holdings
| DINO | HF Sinclair Corp | 0.88% |
| ARW | Arrow Electronics Inc | 0.82% |
| BWA | BorgWarner Inc | 0.80% |
| AVT | Avnet Inc | 0.80% |
| ELAN | Elanco Animal Health Inc | 0.75% |
| IVZ | Invesco Ltd | 0.74% |
| KNX | Knight-Swift Transportation Holdings Inc Class A | 0.70% |
| OVV | Ovintiv Inc | 0.68% |
| JXN | Jackson Financial Inc | 0.65% |
| SWKS | Skyworks Solutions Inc | 0.65% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About DFSV
DFSV (Dimensional US Small Cap Value ETF) is Systematic small-cap value strategy from Dimensional. Managed by Dimensional, the fund carries $27.8B in assets under management, an expense ratio of 0.31%. Its largest holding is HF Sinclair Corp (DINO), which represents 0.9% of the portfolio. Real Estate is the fund's largest sector exposure at 0.8%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.